See What HealthDay Can Do For You
Contact Us

Progression-Free Survival Not Tied to R-CHOP Dose Density

No significant difference for patients with indolent B-cell lymphoma treated with R-CHOP-14 or -21

TUESDAY, Sept. 20 (HealthDay News) -- There is no significant difference in progression-free survival (PFS) for patients with indolent B-cell lymphoma treated with rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) along with granulocyte colony-stimulating factor (G-CSF) every three weeks (R-CHOP-21) or every two weeks (R-CHOP-14), according to a study published online Sept. 19 in the Journal of Clinical Oncology.

Takashi Watanabe, M.D., Ph.D., from the National Cancer Center Hospital in Tokyo, and colleagues investigated whether dose-dense immunochemotherapy with R-CHOP improves PFS in 299 patients with stage III to IV indolent B-cell lymphoma. Participants were randomly assigned to six cycles of R-CHOP-21 or R-CHOP-14 with G-CSF, but no rituximab maintenance. The median follow-up time was 5.2 years.

The investigators found that the two treatment groups had no significant differences in PFS. The median PFS time was 3.7 years for R-CHOP-21 and 4.7 years for R-CHOP-14. For R-CHOP-21, PFS at three and six years was 57 and 41 percent, respectively, compared with 58 and 43 percent, respectively, for R-CHOP-14 (hazard ratio [HR], 0.92; 95 percent confidence interval [CI], 0.68 to 1.25). Neither treatment group achieved the median overall survival (OS) time, with no significant difference in the OS with R-CHOP-21 versus R-CHOP-14 (six-year OS, 87 versus 88 percent, respectively; HR, 1.15; 95 percent CI, 0.57 to 2.30). R-CHOP was feasible in both groups although grade 4 neutropenia and grade 3 infections were more frequent in the R-CHOP-21 group.

"The R-CHOP dose-dense strategy failed to improve PFS of patients with untreated indolent B-cell lymphoma," the authors write.

Several of the study authors disclosed financial ties to Chugai Pharmaceuticals.

Abstract
Full Text
Editorial

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.